Retatrutide, a experimental dual agonist of the GLP-1 receptor and glucose-dependent released polypeptide (GIP) receptor , is showing promising results in preliminary human trials . Recent research indicates that retatrutide may offer substantial benefits for individuals with diabetes , particula